💨 Abstract

Aclaris Therapeutics Inc. (ACRS) reported a first-quarter loss of $15.1 million, or 12 cents per share, beating Wall Street's loss estimates but missing revenue forecasts. The company's revenue was $1.5 million, well below the expected $4.2 million. Its shares closed at $1.25, down from $1.34 a year ago.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖